John G. Houston Sells 31,338 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN) CEO John G. Houston sold 31,338 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the transaction, the chief executive officer now directly owns 1,157,480 shares of the company’s stock, valued at $19,353,065.60. The trade was a 2.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Arvinas Price Performance

Shares of ARVN stock opened at $17.08 on Thursday. The company has a market capitalization of $1.17 billion, a PE ratio of -6.16 and a beta of 1.88. The firm’s 50-day moving average is $18.38 and its two-hundred day moving average is $22.76. Arvinas, Inc. has a 12 month low of $16.07 and a 12 month high of $51.51.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter last year, the firm posted ($2.53) EPS. Sell-side analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current year.

Analyst Ratings Changes

Several analysts recently commented on ARVN shares. Guggenheim reiterated a “buy” rating and set a $57.00 price target on shares of Arvinas in a research report on Wednesday, February 12th. Barclays dropped their target price on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. HC Wainwright reiterated a “buy” rating and issued a $87.00 target price on shares of Arvinas in a research report on Wednesday, December 11th. Stephens initiated coverage on shares of Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $57.00 price objective on shares of Arvinas in a report on Tuesday, February 11th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $60.00.

Institutional Investors Weigh In On Arvinas

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after purchasing an additional 440 shares during the period. Invesco Ltd. lifted its position in Arvinas by 1.6% in the fourth quarter. Invesco Ltd. now owns 37,254 shares of the company’s stock valued at $714,000 after buying an additional 581 shares during the last quarter. Rhumbline Advisers boosted its stake in Arvinas by 0.9% during the fourth quarter. Rhumbline Advisers now owns 87,877 shares of the company’s stock worth $1,685,000 after buying an additional 754 shares during the period. Assenagon Asset Management S.A. boosted its stake in Arvinas by 0.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock worth $2,694,000 after buying an additional 777 shares during the period. Finally, Bank of Montreal Can increased its position in shares of Arvinas by 2.7% during the fourth quarter. Bank of Montreal Can now owns 39,407 shares of the company’s stock valued at $755,000 after acquiring an additional 1,044 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.